States crimp Zyprexa access: Medicaid restrictions cutting into sales of Lilly's top drug

Eli Lilly and Co.'s top seller Zyprexa, pummeled in recent quarters by concerns over side effects, now faces a growing challenge from some of its biggest customers: state Medicaid programs. Citing high costs, more than a half dozen states have moved Zyprexa and other pricey anti-psychotics off preferred drug lists or made it harder for doctors to prescribe them for patients on Medicaid, the state-federal program that provides health care coverage for the poor and disabled. Georgia, for instance, saved...

 

You have accessed IBJ.com Premium online content

IBJ.com Premium online content is identified by locked premium or unlocked premium symbol to the right of the headline. Access to all IBj.com Premium online content requires a paid IBJ.com Premium subscription and the subscriber to be logged in using their email and password. See subscription options below.

Log In if you are a subscriber to IBJ.com Premium Online

...Or choose the IBJ subscription that's right for you:

7 Day Subscription

$4.95 per week

IBJ.com
Premium online

Order Now
   

1 Year Subscription

$1.25 per week

IBJ.com
Premium online

Order Now
 

1 Year Subscription

$1.52 per week

IBJ Print
only

Order Now

 

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT